Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer

BACKGROUND: Radioligand therapy (RLT) with (177)lutetium (Lu)-labelled prostate-specific membrane antigen (PSMA) ligands has been increasingly used in recent years for therapy of metastatic castrate-resistant prostate cancer (mCRPC). Studies have revealed that (177)Lu-PSMA ligand therapy is well tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallyamov, Marat, Meyrick, Danielle, Barley, Jerome, Lenzo, Nat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769531/
https://www.ncbi.nlm.nih.gov/pubmed/33391748
http://dx.doi.org/10.1093/ckj/sfz101

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769531/
https://www.ncbi.nlm.nih.gov/pubmed/33391748
http://dx.doi.org/10.1093/ckj/sfz101

Ejemplares similares